GPHL proactively facilitates the development of stem cell study and precision medicine
2017-11-02 16:26:09 GPHL GPHL
At the Conference, GPHL signed the Eight Party Agreement on International Cooperation in Stem Cell Industrialization with seven other institutions including the Saliai Stem Cell Science and Technology Co。 Ltd, Stanford University, Guangzhou Institute of Biomedicine and Health, Guangdong-Hong Kong-Macau Institute of CNS Regeneration, Guangdong Food and Drug Career College, Oral subsidiary Sun Yat-sen University Hospital and the first affiliated hospital of Jinan University。
Biotechnology is taking an increasing prominent position in future social development and this industry is becoming another forerunner In the same way the information industry has。 According to recent statistical analysis, the stem cell and precision medicine market is expected to reach 500 billion USD worldwide and 100 billion USD in China by 2020。
As one of the largest pharmaceutical companies in China, GPHL is striving to establish a ‘heath industry 4。0’and during the 13th Five-year Plan to achieve sales revenues of 150 billion RMB and make it into the Fortune Global 500。
On the one hand, it will reinforce the four-pronged strategy of Grand Southern TCM, Grand Health Care, Grand Commerce and Grand Medical Treatment. In regards to Grand Southern TCM, in particular, the company will spend more efforts on by facilitating the transformation from a sales-oriented to innovation-driven model.
On the other hand, GPHL will take advantage of its resources and corporate power in industrialization to map out the strategy for new vaccines, stem cell, precision medicine, oncolytic virus, proteinic drugs and medical devices with the joint efforts of Academy of Military Medical Sciences, Wasun Group Co. Ltd and Saliai Stem Cell Science and Technology Co. Ltd. As a result, it will push industrial development in an R&D driven direction.
(Translator: Cheryl Ma; Editors: Simon Haywood, Olivia Yang, Monica Liu)